The Shocking New Tech that Reads Your Mind!

As the world’s largest technology companies continually search for new avenues of innovation and growth, an unlikely field is rapidly emerging as the next major opportunity – neuroscience and the ability to interface directly with the human brain.

While the idea of mind-reading may sound like science fiction, recent breakthroughs powered by artificial intelligence have brought brain-computer interfaces into reality. And the tech giants are taking notice, pouring hundreds of millions into developing these neurotechnologies with an eye on future ecosystems and revenue streams.

A $55 Billion Neurotechnology Gold Rush
According to market research firm Precedence, the global neurotechnology market was valued at around $15 billion in 2023. However, it’s projected to skyrocket to over $55 billion by 2032 as medical applications come to market and consumer use cases emerge.

This rapidly expanding opportunity has kicked off a modern-day gold rush as deep-pocketed companies like Meta, Apple, Amazon, Microsoft, and even Elon Musk’s Neuralink race to stake their claims.

In the medical field, brain-computer interface (BCI) devices that translate neural signals into digital commands are already helping patients with conditions like ALS, strokes, and paralysis to communicate and regain mobility.

But for Big Tech, the true prize lies in developing non-invasive consumer neurotechnology that can seamlessly integrate with devices and software – unlocking new frontiers in computing, gaming, virtual reality, and beyond.

Apple is exploring EEG sensors in AirPods that could monitor a user’s brain waves and mental state. Meta has a team working to decode human perception, using AI to reconstruct images just from people’s neural activity. And Amazon’s Alexa team is researching how to interpret brainwaves for voice-less voice control.

Even video game companies like Activision are eyeing the potential of neural interfaces that could immerse players’ minds directly into virtual environments.

Inside the Mind-Reading Moonshot
While the underlying BCI technology has existed for decades, the rise of advanced AI and machine learning capabilities is what’s truly catalyzing the mind-reading revolution.

By applying powerful neural networks to massive troves of brain signal data, companies aim to identify patterns that can then be translated into computer inputs for controls, communication, or even digital representations of sensory experiences like images and sound.

“We’re just scratching the surface of what neurotechnology combined with AI could enable,” said Dr. Lucy Green, a leading neuroscience researcher at Stanford University. “We may eventually be able to beam our thoughts directly into virtual spaces or machines, and create ultra-personalized experiences based on someone’s unique neural fingerprint.”

Naturally, such godlike capabilities raise serious ethical concerns around data privacy and consent. But for now, Green notes most development is still confined to medical use cases explicitly approved by patients.

Investment Opportunities Galore
For investors, the neurotechnology gold rush presents a multitude of intriguing opportunities across sectors. This includes established healthcare companies like Medtronic working on implantable BCIs, cutting-edge startups pioneering new interfaces and AI models, and even Big Tech bets on developing the next paradigm of human-machine interaction.

According to investment firm Ark, the entire “brain-computer interface” category could scale into a multi-trillion dollar annual revenue opportunity by 2030 if the technology meets its potential.

“It’s such a massive emerging space that will encompass hardware, software, AI capabilities, cloud computing, and likely subscription revenue streams,” said Ark analyst Nick Grous. “Any company that can establish an early lead could be looking at platform ownership.”

While the neuro-revolutions is still in its earliest innings, big bets are already being made behind the scenes at the world’s tech titans. For investors willing to grab a golden neural spike, it may represent one of the final frontiers of monetizing the human experience itself.

Want small cap opportunities delivered straight to your inbox?

Channelchek’s free newsletter will give you exclusive access to our expert research, news, and insights to help you make informed investment decisions.

Get Instant Access

AbbVie’s $8.7 Billion Acquisition of Cerevel Therapeutics: A Game-Changer for Neuroscience Innovations

Pharmaceutical giant AbbVie made a huge splash in the neuroscience space this week with the announcement of its definitive agreement to acquire clinical-stage biotech Cerevel Therapeutics for $8.7 billion. This transforms AbbVie’s position in neuroscience and adds multiple late-stage assets to its pipeline that could drive significant growth over the next decade.

At $45 per share in cash, AbbVie is paying a hefty premium for Cerevel, reflecting its belief in the blockbuster potential of the company’s pipeline. Cerevel has built an impressive roster of new compounds for psychiatric and neurological conditions—areas where AbbVie already has an established presence with treatments for Parkinson’s disease and migraine but now gains even more scale.

The crown jewel of the deal is emraclidine, an investigational antipsychotic for schizophrenia and other psychiatric disorders that could set a new standard of care. Currently in late-stage development, emraclidine has shown early signs of superior efficacy and safety compared to existing schizophrenia meds. With schizophrenia impacting over 5 million people across developed markets, emraclidine represents a multibillion-dollar opportunity for AbbVie commercially.

Beyond emraclidine, Cerevel has a range of other clinical-stage neuro assets that strengthen and complement AbbVie’s pipeline. These include tavapadon for Parkinson’s, CVL-354 for depression, and darigabat for epilepsy—all of which have potential for best-in-class status in their respective categories.

Take a moment to take a look at Noble Capital Capital Market’s Senior Research Analyst Robert LeBoyer’s coverage universe.

According to AbbVie’s chairman and CEO Richard Gonzalez, “Our existing neuroscience portfolio and our combined pipeline with Cerevel represents a significant growth opportunity well into the next decade.” He notes AbbVie’s global commercial infrastructure can help accelerate these drugs to market globally.

Gonzalez has orchestrated a highly successful strategy for AbbVie centered around building global therapeutic franchises in immunology, oncology, and aesthetics. Adding neuroscience as a fourth core franchise has been an ambition for awhile. Between Humira facing biosimilar competition and the need to fuel AbbVie’s next chapter of growth, this acquisition is a strategic step to position neuroscience as a more prominent piece of the puzzle.

For Cerevel, the buyout represents a major win and validation of the platform they have built. As CEO Dr. Ron Renaud comments, “Cerevel has always been committed to transforming what is possible in neuroscience…with AbbVie’s long-standing expertise in developing and commercializing medicines on a global scale, Cerevel’s novel therapies will be well positioned to reach more people.”

Wall Street is reacting positively to the deal announcement, with shares of both companies rising 3-4% the day it was announced. Investors recognize the growth implications and are cheering AbbVie’s move to recharge its pipeline.

While the deal is expected to close in 2024 pending approvals, it marks the continuation of a surge in biotech M&A driven by the appetite of large pharmas to augment their portfolios externally. With over 200 neuroscience programs in mid- to late-stage industrywide across CNS disorders, neurological treatments are having a moment right now. For AbbVie, the Cerevel transaction cements its intent to be at the forefront in capturing this opportunity.

Two Small Cap Biotechs Neumora and RayzeBio File for $200M+ Nasdaq IPOs

Neumora and RayzeBio, two emerging small cap biotech companies, filed on Monday for initial public offerings (IPOs) on the Nasdaq exchange. The firms are seeking to raise over $200 million each through their stock market debuts.

Neumora, a neuroscience startup, plans to offer 14.7 million shares priced between $16-18 to raise around $227 million under the ticker symbol NMRA. RayzeBio, a radiopharmaceuticals developer, aims to raise about $206 million by offering 13.2 million shares priced at $16-18 per share and trading as RYZB.

As small cap biotechs in earlier stages of development, Neumora and RayzeBio are seen as riskier investments than large cap pharmaceutical firms. However, both companies have drugs in late-stage pipelines and will use their IPO proceeds to fund Phase 3 clinical trials.

Neumora’s lead candidate is a depression drug called navacaprant, while RayzeBio is focused on advancing its radioligand therapy RYZ101 for rare tumors through Phase 3. Their ability to progress their pipelines with capital from the IPOs could improve their growth prospects as public companies.

The biotech IPO market has been tepid so far in 2023, making the environment challenging for small cap biotech listings. But Neumora and RayzeBio’s offerings may provide a test for investor appetite for new issues in the sector. Strong demand could reopen the IPO window for other young biotechs seeking to raise growth capital this year.

Take a look at other small cap companies in the biotech sector by exploring Robert LeBoyer’s coverage list.